Information Provided By:
Fly News Breaks for February 5, 2016
BSX
Feb 5, 2016 | 06:36 EDT
Leerink analyst Danielle Antalffy views yesterday's post-earnings selloff in shares of Boston Scientific as overdone. The company reported a solid quarter that showed sustained mid-single-digit organic growth and ongoing positive operating leverage, Antalffy tells investors in a research note. She reiterates an Outperform rating on Boston Scientific with a $21 price target.
News For BSX From the Last 2 Days
BSX
Mar 26, 2024 | 05:33 EDT
Scivita Medical and Boston Scientific joined hands again to sign an expanded strategic cooperation arrangement. The introduction of iterative endoscopic technology has brought about a positive transformation in the field of endoscopy, making it an interventional tool that combines diagnosis and treatment. Under the arrangement, Scivita Medical will expand its relationship with Boston Scientific for strategic co-development and global distribution activities. Such activities may include collaboration on the co-development of future endoscopic devices, and global distribution opportunities for Scivita Medical's single-use endoscope and imaging devices. It is expected that this expanded arrangement will help bring Scivita Medical products to more hospitals and patients throughout China and other global geographies.